{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:44:00Z","timestamp":1788266640284,"version":"build-2803163510"},"reference-count":402,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advancements in immunotherapy, particularly Chimeric antigen receptor (CAR)-T cell therapy and cancer vaccines, have significantly transformed the treatment landscape for leukemia. CAR-T cell therapy, initially promising in hematologic cancers, faces notable obstacles in solid tumors due to the complex and immunosuppressive tumor microenvironment. Challenges include the heterogeneous immune profiles of tumors, variability in antigen expression, difficulties in therapeutic delivery, T cell exhaustion, and reduced cytotoxic activity at the tumor site. Additionally, the physical barriers within tumors and the immunological camouflage used by cancer cells further complicate treatment efficacy. To overcome these hurdles, ongoing research explores the synergistic potential of combining CAR-T cell therapy with cancer vaccines and other therapeutic strategies such as checkpoint inhibitors and cytokine therapy. This review describes the various immunotherapeutic approaches targeting leukemia, emphasizing the roles and interplay of cancer vaccines and CAR-T cell therapy. In addition, by discussing how these therapies individually and collectively contribute to tumor regression, this article aims to highlight innovative treatment paradigms that could enhance clinical outcomes for leukemia patients. This integrative approach promises to pave the way for more effective and durable treatment strategies in the oncology field. These combined immunotherapeutic strategies hold great promise for achieving more complete and lasting remissions in leukemia patients. Future research should prioritize optimizing treatment sequencing, personalizing therapeutic combinations based on individual patient and tumor characteristics, and developing novel strategies to enhance T cell persistence and function within the tumor microenvironment. Ultimately, these efforts will advance the development of more effective and less toxic immunotherapeutic interventions, offering new hope for patients battling this challenging disease.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s40164-025-00662-3","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:33:26Z","timestamp":1747456406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines"],"prefix":"10.1186","volume":"14","author":[{"given":"Kiavash","family":"Hushmandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas Ali","family":"Imani Fooladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel J.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najma","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"1","key":"662_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther. 2023;8(1):306. https:\/\/doi.org\/10.1038\/s41392-023-01521-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"662_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"662_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","volume":"108","author":"S Kayser","year":"2023","unstructured":"Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108(2):308\u201320. https:\/\/doi.org\/10.3324\/haematol.2022.280801.","journal-title":"Haematologica"},{"issue":"1","key":"662_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.15614","volume":"184","author":"HW Wang","year":"2019","unstructured":"Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol. 2019;184(1):45\u201359. https:\/\/doi.org\/10.1111\/bjh.15614.","journal-title":"Br J Haematol"},{"key":"662_CR5","doi-asserted-by":"crossref","unstructured":"Ansell SM, editor. Hodgkin lymphoma: diagnosis and treatment. Mayo Clinic Proceedings. Elsevier; 2015.","DOI":"10.1016\/j.mayocp.2015.07.005"},{"key":"662_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2022.04.007","volume":"346","author":"M Sharma","year":"2022","unstructured":"Sharma M, Bakshi AK, Mittapelly N, Gautam S, Marwaha D, Rai N, et al. Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. J Control Release. 2022;346:43\u201370. https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.007.","journal-title":"J Control Release"},{"issue":"7171","key":"662_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","volume":"450","author":"CM Koebel","year":"2007","unstructured":"Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity aintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903\u20137. https:\/\/doi.org\/10.1038\/nature06309.","journal-title":"Nature"},{"key":"662_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143296","author":"M von Locquenghien","year":"2021","unstructured":"von Locquenghien M, Rozalen C, Celia-Terrassa T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI143296.","journal-title":"J Clin Invest"},{"key":"662_CR9","volume-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies. Seminars in cancer biology","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, editors. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Seminars in cancer biology. Elsevier; 2015."},{"issue":"10","key":"662_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri1936","volume":"6","author":"L Zitvogel","year":"2006","unstructured":"Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715\u201327. https:\/\/doi.org\/10.1038\/nri1936.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"662_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137\u201348. https:\/\/doi.org\/10.1016\/j.immuni.2004.07.017.","journal-title":"Immunity"},{"issue":"1","key":"662_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"issue":"1","key":"662_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","volume":"39","author":"GT Motz","year":"2013","unstructured":"Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61\u201373. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.005.","journal-title":"Immunity"},{"key":"662_CR14","volume-title":"Cancer immunotherapy","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Cancer immunotherapy. American Association for the Advancement of Science; 2013."},{"key":"662_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/science.297.5589.1973a","volume-title":"Select T cells, given space, shrink tumors","author":"J Couzin","year":"2002","unstructured":"Couzin J. Select T cells, given space, shrink tumors. American Association for the Advancement of Science; 2002."},{"issue":"4","key":"662_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrc3907","volume":"15","author":"P Bachireddy","year":"2015","unstructured":"Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015;15(4):201\u201315.","journal-title":"Nat Rev Cancer"},{"key":"662_CR17","doi-asserted-by":"publisher","first-page":"1546172","DOI":"10.3389\/fimmu.2025.1546172","volume":"16","author":"S Gomez-Melero","year":"2025","unstructured":"Gomez-Melero S, Hassouneh F, Vallejo-Bermudez IM, Aguera-Morales E, Solana R, Caballero-Villarraso J. Tandem CAR-T cell therapy: recent advances and current challenges. Front Immunol. 2025;16:1546172. https:\/\/doi.org\/10.3389\/fimmu.2025.1546172.","journal-title":"Front Immunol"},{"issue":"2","key":"662_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.7868\/S0026898417020148","volume":"51","author":"SV Kulemzin","year":"2017","unstructured":"Kulemzin SV, Kuznetsova VV, Mamonkin M, Taranin AV, Gorchakov AA. CAR T-cell therapy: balance of efficacy and safety. Mol Biol (Mosk). 2017;51(2):274\u201387. https:\/\/doi.org\/10.7868\/S0026898417020148.","journal-title":"Mol Biol (Mosk)"},{"issue":"15","key":"662_CR19","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186(15):3148-65 e20. https:\/\/doi.org\/10.1016\/j.cell.2023.06.002.","journal-title":"Cell"},{"key":"662_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925985","volume":"13","author":"MP Jogalekar","year":"2022","unstructured":"Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022;13: 925985. https:\/\/doi.org\/10.3389\/fimmu.2022.925985.","journal-title":"Front Immunol"},{"issue":"10","key":"662_CR21","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Foa R, Maurer J, O\u2019Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232\u201373. https:\/\/doi.org\/10.1007\/s12325-017-0612-x.","journal-title":"Adv Ther"},{"issue":"Suppl 5","key":"662_CR22","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116\u201325. https:\/\/doi.org\/10.1093\/annonc\/mdv304.","journal-title":"Ann Oncol"},{"issue":"7","key":"662_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388. https:\/\/doi.org\/10.1016\/S1470-2045(20)30225-4.","journal-title":"Lancet Oncol"},{"issue":"8","key":"662_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1606038.","journal-title":"N Engl J Med"},{"key":"662_CR25","first-page":"205","volume-title":"Bispecific T-cell engagers (BiTEs) in immunotherapy. Critical developments in cancer immunotherapy","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, La\u2019ah AS, Ahmadieh-Yazdi A, Tanzadehpanah H, Mahaki H, Manoochehri H, et al. Bispecific T-cell engagers (BiTEs) in immunotherapy. Critical developments in cancer immunotherapy. IGI Global; 2024. p. 205\u201334."},{"issue":"1","key":"662_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366.","journal-title":"Lancet Oncol"},{"key":"662_CR27","doi-asserted-by":"publisher","first-page":"1274088","DOI":"10.3389\/fphar.2023.1274088","volume":"14","author":"F Riccardi","year":"2023","unstructured":"Riccardi F, Dal Bo M, Macor P, Toffoli G. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. Front Pharmacol. 2023;14:1274088. https:\/\/doi.org\/10.3389\/fphar.2023.1274088.","journal-title":"Front Pharmacol"},{"issue":"1","key":"662_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"662_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41417-021-00295-8","volume":"29","author":"Y Wu","year":"2022","unstructured":"Wu Y, Chen D, Lu Y, Dong SC, Ma R, Tang WY, et al. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. Cancer Gene Ther. 2022;29(2):167\u201377. https:\/\/doi.org\/10.1038\/s41417-021-00295-8.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"662_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00277-022-05054-9","volume":"102","author":"HM Prince","year":"2023","unstructured":"Prince HM, Hutchings M, Domingo-Domenech E, Eichenauer DA, Advani R. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Ann Hematol. 2023;102(1):13\u201329. https:\/\/doi.org\/10.1007\/s00277-022-05054-9.","journal-title":"Ann Hematol"},{"issue":"4","key":"662_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378(4):331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1708984.","journal-title":"N Engl J Med"},{"issue":"10168","key":"662_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2.","journal-title":"Lancet"},{"issue":"1","key":"662_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15(1):163. https:\/\/doi.org\/10.1186\/s13045-022-01376-3.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"662_CR34","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","volume":"16","author":"YR Li","year":"2025","unstructured":"Li YR, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z, et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun. 2025;16(1):1248. https:\/\/doi.org\/10.1038\/s41467-025-56270-6.","journal-title":"Nat Commun"},{"issue":"1","key":"662_CR35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8(1):450. https:\/\/doi.org\/10.1038\/s41392-023-01674-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"662_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13326-024-00312-3","volume":"15","author":"J Zheng","year":"2024","unstructured":"Zheng J, Li X, Masci AM, Kahn H, Huffman A, Asfaw E, et al. Empowering standardization of cancer vaccines through ontology: enhanced modeling and data analysis. J Biomed Semant. 2024;15(1):12.","journal-title":"J Biomed Semant"},{"issue":"1","key":"662_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/BF02983241","volume":"78","author":"Y Oka","year":"2003","unstructured":"Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol. 2003;78(1):56\u201361. https:\/\/doi.org\/10.1007\/BF02983241.","journal-title":"Int J Hematol"},{"issue":"38","key":"662_CR38","doi-asserted-by":"publisher","first-page":"13885","DOI":"10.1073\/pnas.0405884101","volume":"101","author":"Y Oka","year":"2004","unstructured":"Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms\u2019 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101(38):13885\u201390. https:\/\/doi.org\/10.1073\/pnas.0405884101.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"662_CR39","doi-asserted-by":"publisher","first-page":"2296735","DOI":"10.1080\/21645515.2023.2296735","volume":"20","author":"M Ogasawara","year":"2024","unstructured":"Ogasawara M. Wilms\u2019 tumor 1\u2014targeting cancer vaccine: recent advancements and future perspectives. Hum Vaccin Immunother. 2024;20(1):2296735. https:\/\/doi.org\/10.1080\/21645515.2023.2296735.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"662_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68\u201383. https:\/\/doi.org\/10.1182\/blood-2017-07-740993.","journal-title":"Blood"},{"issue":"8","key":"662_CR41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00262-024-03734-1","volume":"73","author":"Y Chen","year":"2024","unstructured":"Chen Y, Han H, Cheng J, Cheng Q, Zhu S, Zhan P, et al. Efficacy and safety of anti-PD-1\/PD-L1-based dual immunotherapies versus PD-1\/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis. Cancer Immunol Immunother. 2024;73(8):155.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"662_CR42","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/0008-5472.CAN-23-2664","volume":"84","author":"TA Lee","year":"2024","unstructured":"Lee TA, Tsai EY, Liu SH, Hsu Hung SD, Chang SJ, Chao CH, et al. Post-translational modification of PD-1: potential targets for cancer immunotherapy. Cancer Res. 2024;84(6):800\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2664.","journal-title":"Cancer Res"},{"key":"662_CR43","doi-asserted-by":"publisher","DOI":"10.2174\/1389201019666180418095526","author":"M Sahlolbei","year":"2024","unstructured":"Sahlolbei M, Ahmadieh-Yazdi A, Rostamipoor M, Manoochehri H, Mahaki H, Tanzadehpanah H, et al. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2024. https:\/\/doi.org\/10.2174\/1389201019666180418095526.","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"662_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-017-0453-8","volume":"10","author":"A Im","year":"2017","unstructured":"Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017;10(1):94. https:\/\/doi.org\/10.1186\/s13045-017-0453-8.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"662_CR45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen Z, Prinz I, D\u00e9chanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discovery. 2020;19(3):169\u201384.","journal-title":"Nat Rev Drug Discovery"},{"key":"662_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","volume":"472","author":"W Wang","year":"2020","unstructured":"Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020;472:175\u201380. https:\/\/doi.org\/10.1016\/j.canlet.2019.11.033.","journal-title":"Cancer Lett"},{"issue":"4","key":"662_CR47","doi-asserted-by":"publisher","first-page":"966","DOI":"10.20892\/j.issn.2095-3941.2020.0801","volume":"18","author":"Z Xu","year":"2021","unstructured":"Xu Z, Huang X. Cellular immunotherapy for hematological malignancy: recent progress and future perspectives. Cancer Biol Med. 2021;18(4):966\u201380. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0801.","journal-title":"Cancer Biol Med"},{"issue":"7897","key":"662_CR48","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602(7897):503\u20139.","journal-title":"Nature"},{"issue":"1","key":"662_CR49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107(1):112\u201322. https:\/\/doi.org\/10.1002\/cpt.1674.","journal-title":"Clin Pharmacol Ther"},{"key":"662_CR50","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049.","journal-title":"Front Immunol"},{"issue":"1","key":"662_CR51","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","volume":"12","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? Stem Cell Res Ther. 2021;12(1):527.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"662_CR52","doi-asserted-by":"publisher","first-page":"10808","DOI":"10.1038\/s41598-019-47149-w","volume":"9","author":"AD Kosinska","year":"2019","unstructured":"Kosinska AD, Moeed A, Kallin N, Festag J, Su J, Steiger K, et al. Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. Sci Rep. 2019;9(1):10808. https:\/\/doi.org\/10.1038\/s41598-019-47149-w.","journal-title":"Sci Rep"},{"issue":"2","key":"662_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.hoc.2018.12.001","volume":"33","author":"PJ DeMaria","year":"2019","unstructured":"DeMaria PJ, Bilusic M. Cancer vaccines. Hematol Oncol Clin North Am. 2019;33(2):199\u2013214. https:\/\/doi.org\/10.1016\/j.hoc.2018.12.001.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4682","key":"662_CR54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/184291a0","volume":"184","author":"LJ Old","year":"1959","unstructured":"Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959;184(4682):291\u20132. https:\/\/doi.org\/10.1038\/184291a0.","journal-title":"Nature"},{"issue":"5","key":"662_CR55","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25(5):814\u201324. https:\/\/doi.org\/10.1038\/s41591-019-0410-x.","journal-title":"Nat Med"},{"issue":"28","key":"662_CR56","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","volume":"28","author":"JD Brody","year":"2010","unstructured":"Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study. J Clin Oncol. 2010;28(28):4324\u201332. https:\/\/doi.org\/10.1200\/JCO.2010.28.9793.","journal-title":"J Clin Oncol"},{"issue":"5","key":"662_CR57","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med"},{"issue":"1","key":"662_CR58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood.V58.1.141.141","volume":"58","author":"J Ritz","year":"1981","unstructured":"Ritz J, Pesando JM, Sallan SE, Clavell LA, Notis-McConarty J, Rosenthal P, Schlossman SF. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981;58(1):141\u201352.","journal-title":"Blood"},{"issue":"10","key":"662_CR59","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4079.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"662_CR60","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"662_CR61","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3(8):911\u201326. https:\/\/doi.org\/10.1038\/s43018-022-00418-6.","journal-title":"Nat Cancer"},{"issue":"13","key":"662_CR62","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"issue":"8","key":"662_CR63","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"issue":"10","key":"662_CR64","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/13928","volume":"5","author":"M Bendandi","year":"1999","unstructured":"Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171\u20137. https:\/\/doi.org\/10.1038\/13928.","journal-title":"Nat Med"},{"issue":"4","key":"662_CR65","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"issue":"9","key":"662_CR66","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1172\/JCI80009","volume":"125","author":"CJ Melief","year":"2015","unstructured":"Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401\u201312. https:\/\/doi.org\/10.1172\/JCI80009.","journal-title":"J Clin Invest"},{"issue":"6","key":"662_CR67","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-19-1874","volume":"26","author":"P Malekzadeh","year":"2020","unstructured":"Malekzadeh P, Yossef R, Cafri G, Paria BC, Lowery FJ, Jafferji M, et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens. Clin Cancer Res. 2020;26(6):1267\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1874.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"662_CR68","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924\u201338.","journal-title":"Immunity"},{"issue":"5904","key":"662_CR69","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322(5904):1097\u2013100. https:\/\/doi.org\/10.1126\/science.1164206.","journal-title":"Science"},{"key":"662_CR70","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.tips.2024.12.004","volume":"46","author":"Y-R Li","year":"2024","unstructured":"Li Y-R, Lyu Z, Shen X, Fang Y, Yang L. Boosting CAR-T cell therapy through vaccine synergy. Trends Pharmacol Sci. 2024;46:180\u201399.","journal-title":"Trends Pharmacol Sci"},{"issue":"17","key":"662_CR71","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0737.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"662_CR72","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","volume":"4","author":"A Peri","year":"2023","unstructured":"Peri A, Salomon N, Wolf Y, Kreiter S, Diken M, Samuels Y. The landscape of T cell antigens for cancer immunotherapy. Nat Cancer. 2023;4(7):937\u201354. https:\/\/doi.org\/10.1038\/s43018-023-00588-x.","journal-title":"Nat Cancer"},{"issue":"1","key":"662_CR73","doi-asserted-by":"publisher","first-page":"ltad030","DOI":"10.1093\/immadv\/ltad030","volume":"4","author":"S Makker","year":"2024","unstructured":"Makker S, Galley C, Bennett CL. Cancer vaccines: from an immunology perspective. Immunother Adv. 2024;4(1):ltad030. https:\/\/doi.org\/10.1093\/immadv\/ltad030.","journal-title":"Immunother Adv"},{"key":"662_CR74","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3389\/fonc.2020.01326","volume":"10","author":"Y Wan","year":"2020","unstructured":"Wan Y, Zhang Y, Wang G, Mwangi PM, Cai H, Li R. Recombinant KRAS G12D protein vaccines elicit significant anti-tumor effects in mouse CT26 tumor models. Front Oncol. 2020;10:1326. https:\/\/doi.org\/10.3389\/fonc.2020.01326.","journal-title":"Front Oncol"},{"issue":"7","key":"662_CR75","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/s43018-023-00591-2","volume":"4","author":"I Mota","year":"2023","unstructured":"Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E, et al. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat Cancer. 2023;4(7):1016\u201335. https:\/\/doi.org\/10.1038\/s43018-023-00591-2.","journal-title":"Nat Cancer"},{"issue":"7957","key":"662_CR76","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-023-05771-9","volume":"616","author":"KW Ng","year":"2023","unstructured":"Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023;616(7957):563\u201373. https:\/\/doi.org\/10.1038\/s41586-023-05771-9.","journal-title":"Nature"},{"issue":"7852","key":"662_CR77","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41586-021-03368-8","volume":"592","author":"S Kalaora","year":"2021","unstructured":"Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021;592(7852):138\u201343. https:\/\/doi.org\/10.1038\/s41586-021-03368-8.","journal-title":"Nature"},{"issue":"5","key":"662_CR78","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1172\/JCI99538","volume":"129","author":"F Chen","year":"2019","unstructured":"Chen F, Zou Z, Du J, Su S, Shao J, Meng F, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest. 2019;129(5):2056\u201370. https:\/\/doi.org\/10.1172\/JCI99538.","journal-title":"J Clin Invest"},{"issue":"9","key":"662_CR79","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","volume":"125","author":"MM Gubin","year":"2015","unstructured":"Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413\u201321. https:\/\/doi.org\/10.1172\/JCI80008.","journal-title":"J Clin Invest"},{"issue":"7963","key":"662_CR80","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"issue":"11","key":"662_CR81","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130(11):5976\u201388. https:\/\/doi.org\/10.1172\/JCI134915.","journal-title":"J Clin Invest"},{"issue":"7528","key":"662_CR82","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572\u20136. https:\/\/doi.org\/10.1038\/nature14001.","journal-title":"Nature"},{"issue":"6236","key":"662_CR83","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803\u20138. https:\/\/doi.org\/10.1126\/science.aaa3828.","journal-title":"Science"},{"issue":"4","key":"662_CR84","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329. https:\/\/doi.org\/10.1038\/s41571-020-00460-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"662_CR85","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang F, Schr\u00f6rs B, L\u00f6wer M, T\u00fcreci \u00d6, Sahin U. Identification of neoantigens for individualised cancer immunotherapy. Nat Rev Drug Discovery. 2022;21(4):261.","journal-title":"Nat Rev Drug Discovery"},{"issue":"11","key":"662_CR86","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","volume":"56","author":"M Muller","year":"2023","unstructured":"Muller M, Huber F, Arnaud M, Kraemer AI, Altimiras ER, Michaux J, et al. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction. Immunity. 2023;56(11):2650-63 e6. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.002.","journal-title":"Immunity"},{"issue":"6","key":"662_CR87","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2326-6066.CIR-13-0227","volume":"2","author":"EF Fritsch","year":"2014","unstructured":"Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014;2(6):522\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0227.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"662_CR88","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4161\/hv.26568","volume":"10","author":"S Srivatsan","year":"2014","unstructured":"Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, Selvaraj P. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother. 2014;10(1):52\u201363. https:\/\/doi.org\/10.4161\/hv.26568.","journal-title":"Hum Vaccin Immunother"},{"issue":"23","key":"662_CR89","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1406498.","journal-title":"N Engl J Med"},{"issue":"6230","key":"662_CR90","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348.","journal-title":"Science"},{"issue":"25","key":"662_CR91","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131. https:\/\/doi.org\/10.1056\/NEJMc1713444.","journal-title":"N Engl J Med"},{"key":"662_CR92","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.87465.2.sa2","author":"C Gurjao","year":"2023","unstructured":"Gurjao C, Tsukrov D, Imakaev M, Luquette LJ, Mirny LA. Is tumor mutational burden predictive of response to immunotherapy? Elife. 2023. https:\/\/doi.org\/10.7554\/eLife.87465.2.sa2.","journal-title":"Elife"},{"issue":"2","key":"662_CR93","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","volume":"29","author":"N Niknafs","year":"2023","unstructured":"Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat Med. 2023;29(2):440\u20139. https:\/\/doi.org\/10.1038\/s41591-022-02163-w.","journal-title":"Nat Med"},{"issue":"2","key":"662_CR94","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154\u201373.","journal-title":"Cancer Cell"},{"issue":"3","key":"662_CR95","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596-614 e14. https:\/\/doi.org\/10.1016\/j.cell.2021.01.002.","journal-title":"Cell"},{"issue":"7917","key":"662_CR96","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-022-04839-2","volume":"607","author":"AM Jaeger","year":"2022","unstructured":"Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, et al. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature. 2022;607(7917):149\u201355. https:\/\/doi.org\/10.1038\/s41586-022-04839-2.","journal-title":"Nature"},{"issue":"4","key":"662_CR97","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.4049\/jimmunol.1101644","volume":"188","author":"X Zhao","year":"2012","unstructured":"Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, et al. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol. 2012;188(4):1782\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1101644.","journal-title":"J Immunol"},{"issue":"19","key":"662_CR98","doi-asserted-by":"publisher","first-page":"8076","DOI":"10.1158\/0008-5472.CAN-08-0387","volume":"68","author":"H Komita","year":"2008","unstructured":"Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, Alber S, et al. CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Res. 2008;68(19):8076\u201384. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0387.","journal-title":"Cancer Res"},{"issue":"9","key":"662_CR99","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.4049\/jimmunol.156.9.3151","volume":"156","author":"ML Disis","year":"1996","unstructured":"Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2\/neu, oncogenic self-protein. J Immunol. 1996;156(9):3151\u20138.","journal-title":"J Immunol"},{"issue":"4","key":"662_CR100","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1158\/1078-0432.CCR-08-1231","volume":"15","author":"JM Kirkwood","year":"2009","unstructured":"Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+\/-granulocyte-monocyte colony-stimulating factor and\/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009;15(4):1443\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1231.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"662_CR101","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-13-0002","volume":"19","author":"CL Slingluff Jr","year":"2013","unstructured":"Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013;19(15):4228\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0002.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"662_CR102","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.2013.54.0526","volume":"32","author":"IF Pollack","year":"2014","unstructured":"Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014;32(19):2050\u20138. https:\/\/doi.org\/10.1200\/JCO.2013.54.0526.","journal-title":"J Clin Oncol"},{"issue":"3","key":"662_CR103","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"H Okada","year":"2011","unstructured":"Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.30.7744.","journal-title":"J Clin Oncol"},{"issue":"3","key":"662_CR104","first-page":"998","volume":"9","author":"LH Butterfield","year":"2003","unstructured":"Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003;9(3):998\u20131008.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"662_CR105","doi-asserted-by":"publisher","first-page":"11895","DOI":"10.1073\/pnas.1006500107","volume":"107","author":"MJ Welters","year":"2010","unstructured":"Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A. 2010;107(26):11895\u20139. https:\/\/doi.org\/10.1073\/pnas.1006500107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"662_CR106","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa0810097.","journal-title":"N Engl J Med"},{"issue":"10","key":"662_CR107","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/eji.201343324","volume":"43","author":"RA Rosalia","year":"2013","unstructured":"Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol. 2013;43(10):2554\u201365.","journal-title":"Eur J Immunol"},{"issue":"5","key":"662_CR108","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","volume":"17","author":"CL Slingluff Jr","year":"2011","unstructured":"Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 2011;17(5):343\u201350. https:\/\/doi.org\/10.1097\/PPO.0b013e318233e5b2.","journal-title":"Cancer J"},{"issue":"8","key":"662_CR109","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.2883","volume":"18","author":"S Walter","year":"2012","unstructured":"Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18(8):1254\u201361. https:\/\/doi.org\/10.1038\/nm.2883.","journal-title":"Nat Med"},{"issue":"1","key":"662_CR110","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","volume":"6","author":"T Kimura","year":"2013","unstructured":"Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2013;6(1):18\u201326. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-12-0275.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"662_CR111","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2796.2010.02317.x","volume":"269","author":"K Palucka","year":"2011","unstructured":"Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011;269(1):64\u201373. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02317.x.","journal-title":"J Intern Med"},{"issue":"4","key":"662_CR112","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265\u201377. https:\/\/doi.org\/10.1038\/nrc3258.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"662_CR113","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","volume":"39","author":"K Palucka","year":"2013","unstructured":"Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38\u201348. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.004.","journal-title":"Immunity"},{"issue":"1","key":"662_CR114","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nm0196-52","volume":"2","author":"FJ Hsu","year":"1996","unstructured":"Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2(1):52\u20138. https:\/\/doi.org\/10.1038\/nm0196-52.","journal-title":"Nat Med"},{"issue":"11","key":"662_CR115","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1158\/0008-5472.CAN-05-3905","volume":"66","author":"J Wierecky","year":"2006","unstructured":"Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66(11):5910\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3905.","journal-title":"Cancer Res"},{"issue":"31","key":"662_CR116","doi-asserted-by":"publisher","first-page":"13824","DOI":"10.1073\/pnas.1008051107","volume":"107","author":"VF Van Tendeloo","year":"2010","unstructured":"Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms\u2019 tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010;107(31):13824\u20139. https:\/\/doi.org\/10.1073\/pnas.1008051107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"662_CR117","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nm0398-328","volume":"4","author":"FO Nestle","year":"1998","unstructured":"Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells. Nat Med. 1998;4(3):328\u201332.","journal-title":"Nat Med"},{"issue":"17","key":"662_CR118","first-page":"6451","volume":"61","author":"J Banchereau","year":"2001","unstructured":"Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61(17):6451\u20138.","journal-title":"Cancer Res"},{"issue":"13","key":"662_CR119","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","volume":"19","author":"J Rosenblatt","year":"2013","unstructured":"Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, et al. Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013;19(13):3640\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0282.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"662_CR120","doi-asserted-by":"publisher","DOI":"10.4161\/onci.25771","volume":"2","author":"E Vacchelli","year":"2013","unstructured":"Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucikova J, Cremer I, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013;2(10): e25771. https:\/\/doi.org\/10.4161\/onci.25771.","journal-title":"Oncoimmunology"},{"issue":"8","key":"662_CR121","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90(8):3539\u201343. https:\/\/doi.org\/10.1073\/pnas.90.8.3539.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"662_CR122","first-page":"3931","volume":"52","author":"WH McBride","year":"1992","unstructured":"McBride WH, Thacker JD, Comora S, Economou JS, Kelley D, Hogge D, et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res. 1992;52(14):3931\u20137.","journal-title":"Cancer Res"},{"issue":"22","key":"662_CR123","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1073\/pnas.95.22.13141","volume":"95","author":"R Soiffer","year":"1998","unstructured":"Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998;95(22):13141\u20136. https:\/\/doi.org\/10.1073\/pnas.95.22.13141.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"662_CR124","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/jnci\/djh028","volume":"96","author":"J Nemunaitis","year":"2004","unstructured":"Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst. 2004;96(4):326\u201331. https:\/\/doi.org\/10.1093\/jnci\/djh028.","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"662_CR125","doi-asserted-by":"publisher","first-page":"8978","DOI":"10.1200\/JCO.2005.01.6816","volume":"23","author":"RM Luiten","year":"2005","unstructured":"Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol. 2005;23(35):8978\u201391. https:\/\/doi.org\/10.1200\/JCO.2005.01.6816.","journal-title":"J Clin Oncol"},{"issue":"3","key":"662_CR126","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","volume":"18","author":"DT Le","year":"2012","unstructured":"Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18(3):858\u201368. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2121.","journal-title":"Clin Cancer Res"},{"key":"662_CR127","volume-title":"Clinical development of listeria monocytogenes\u2013based immunotherapies. Seminars in oncology","year":"2012","unstructured":"Le DT, Dubensky TW Jr, Brockstedt DG, editors. Clinical development of listeria monocytogenes\u2013based immunotherapies. Seminars in oncology. Elsevier; 2012."},{"issue":"22","key":"662_CR128","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-10-2138","volume":"16","author":"RJ Barth Jr","year":"2010","unstructured":"Barth RJ Jr, Fisher DA, Wallace PK, Channon JY, Noelle RJ, Gui J, Ernstoff MS. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res. 2010;16(22):5548\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2138.","journal-title":"Clin Cancer Res"},{"issue":"9236","key":"662_CR129","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(00)02762-8","volume":"356","author":"J Geiger","year":"2000","unstructured":"Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet. 2000;356(9236):1163\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(00)02762-8.","journal-title":"Lancet"},{"issue":"3","key":"662_CR130","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/01.cji.0000197097.46100.bb","volume":"29","author":"TS Kim","year":"2006","unstructured":"Kim TS, Chopra A, O-Sullivan IS, Cohen EP. Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells: Enrichment of the vaccine for immunotherapeutic cells. J Immunother. 2006;29(3):261\u201373. https:\/\/doi.org\/10.1097\/01.cji.0000197097.46100.bb.","journal-title":"J Immunother"},{"key":"662_CR131","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h988","volume":"350","author":"LH Butterfield","year":"2015","unstructured":"Butterfield LH. Cancer vaccines. BMJ. 2015;350: h988. https:\/\/doi.org\/10.1136\/bmj.h988.","journal-title":"BMJ"},{"issue":"6","key":"662_CR132","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360\u201378. https:\/\/doi.org\/10.1038\/s41568-021-00346-0.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"662_CR133","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"662_CR134","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/vaccines8030391","volume":"8","author":"L Cheng","year":"2020","unstructured":"Cheng L, Wang Y, Du J. Human papillomavirus vaccines: an updated review. Vaccines (Basel). 2020;8(3):391. https:\/\/doi.org\/10.3390\/vaccines8030391.","journal-title":"Vaccines (Basel)"},{"key":"662_CR135","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","volume":"65","author":"E Ylosmaki","year":"2020","unstructured":"Ylosmaki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol. 2020;65:25\u201336. https:\/\/doi.org\/10.1016\/j.copbio.2019.11.016.","journal-title":"Curr Opin Biotechnol"},{"key":"662_CR136","doi-asserted-by":"publisher","DOI":"10.1177\/1178122X20913274","author":"PH Mody","year":"2020","unstructured":"Mody PH, Pathak S, Hanson LK, Spencer JV. Herpes simplex virus: a versatile tool for insights into evolution, gene delivery, and tumor immunotherapy. Virol Res Treat. 2020. https:\/\/doi.org\/10.1177\/1178122X20913274.","journal-title":"Virol Res Treat"},{"issue":"12","key":"662_CR137","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3390\/cancers14122994","volume":"14","author":"K Barbullushi","year":"2022","unstructured":"Barbullushi K, Rampi N, Serpenti F, Scium\u00e8 M, Fabris S, De Roberto P, Fracchiolla NS. Vaccination therapy for acute myeloid leukemia: where do we stand? Cancers. 2022;14(12):2994.","journal-title":"Cancers"},{"issue":"10","key":"662_CR138","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2217\/imt-2020-0277","volume":"13","author":"M Wu","year":"2021","unstructured":"Wu M, Wang S, Chen JY, Zhou LJ, Guo ZW, Li YH. Therapeutic cancer vaccine therapy for acute myeloid leukemia. Immunotherapy. 2021;13(10):863\u201377. https:\/\/doi.org\/10.2217\/imt-2020-0277.","journal-title":"Immunotherapy"},{"issue":"26","key":"662_CR139","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","volume":"113","author":"U Keilholz","year":"2009","unstructured":"Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26):6541\u20138. https:\/\/doi.org\/10.1182\/blood-2009-02-202598.","journal-title":"Blood"},{"key":"662_CR140","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2018-99-110013","volume":"132","author":"M Yamaguchi","year":"2018","unstructured":"Yamaguchi M, Takezako N, Kiguchi T, Miyawaki S, Heike Y, Mitsuki K, et al. Phase II trial of a peptide vaccine, Ocv-501 in elderly patients with acute myeloid leukemia. Blood. 2018;132:29.","journal-title":"Blood"},{"issue":"7","key":"662_CR141","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ajh.24014","volume":"90","author":"J Brayer","year":"2015","unstructured":"Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT 1 vaccination in AML and MDS: a pilot trial with synthetic analog peptides. Am J Hematol. 2015;90(7):602\u20137.","journal-title":"Am J Hematol"},{"issue":"3","key":"662_CR142","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bjh.12637","volume":"164","author":"B Uttenthal","year":"2014","unstructured":"Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, et al. Wilms\u2019 Tumour 1 (WT 1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT 1-specific immune responses. Br J Haematol. 2014;164(3):366\u201375.","journal-title":"Br J Haematol"},{"issue":"11","key":"662_CR143","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00262-008-0561-y","volume":"57","author":"M Palma","year":"2008","unstructured":"Palma M, Adamson L, Hansson L, Kokhaei P, Rezvany R, Mellstedt H, et al. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. Cancer Immunol Immunother. 2008;57(11):1705\u201310. https:\/\/doi.org\/10.1007\/s00262-008-0561-y.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"662_CR144","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.exphem.2006.10.006","volume":"35","author":"P Kokhaei","year":"2007","unstructured":"Kokhaei P, Palma M, Hansson L, \u00d6sterborg A, Mellstedt H, Choudhury A. Telomerase (hTERT 611\u2013626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol. 2007;35(2):297\u2013304.","journal-title":"Exp Hematol"},{"issue":"5","key":"662_CR145","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/sj.leu.2402913","volume":"17","author":"P Kokhaei","year":"2003","unstructured":"Kokhaei P, Rezvany M, Virving L, Choudhury A, Rabbani H, \u00d6sterborg A, Mellstedt H. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell\u2013tumour hybrids in B-CLL. Leukemia. 2003;17(5):894\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"662_CR146","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1365-2141.2007.06547.x","volume":"137","author":"J Westermann","year":"2007","unstructured":"Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr\/abl+ chronic myeloid leukaemia. Br J Haematol. 2007;137(4):297\u2013306. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06547.x.","journal-title":"Br J Haematol"},{"issue":"3","key":"662_CR147","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","volume":"103","author":"K Cathcart","year":"2004","unstructured":"Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103(3):1037\u201342. https:\/\/doi.org\/10.1182\/blood-2003-03-0954.","journal-title":"Blood"},{"issue":"8","key":"662_CR148","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00262-013-1438-2","volume":"62","author":"W Hobo","year":"2013","unstructured":"Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, et al. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother. 2013;62(8):1381\u201392. https:\/\/doi.org\/10.1007\/s00262-013-1438-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"662_CR149","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14653240902960411","volume":"11","author":"A Van Driessche","year":"2009","unstructured":"Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy. 2009;11(5):653\u201368. https:\/\/doi.org\/10.1080\/14653240902960411.","journal-title":"Cytotherapy"},{"key":"662_CR150","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-011-1149-5","volume":"61","author":"M Palma","year":"2012","unstructured":"Palma M, Hansson L, Choudhury A, N\u00e4sman-Glaser B, Eriksson I, Adamson L, et al. Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. Cancer Immunol Immunother. 2012;61:865\u201379.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"662_CR151","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/leu.2008.29","volume":"22","author":"I Hus","year":"2008","unstructured":"Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+ CD25+ FoxP3+ regulatory T cells toward an antileukemia response. Leukemia. 2008;22(5):1007\u201317.","journal-title":"Leukemia"},{"issue":"1","key":"662_CR152","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2008-06-165654","volume":"113","author":"M Di Nicola","year":"2009","unstructured":"Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2009;113(1):18\u201327. https:\/\/doi.org\/10.1182\/blood-2008-06-165654.","journal-title":"Blood"},{"issue":"21","key":"662_CR153","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1182\/blood.V122.21.3928.3928","volume":"122","author":"J Rosenblatt","year":"2013","unstructured":"Rosenblatt J, Stone RM, Uhl L, Neuberg DS, Vasir B, Somaiya P, et al. Clinical trial evaluating DC\/AML fusion cell vaccination in AML patients. Blood. 2013;122(21):3928.","journal-title":"Blood"},{"issue":"37","key":"662_CR154","doi-asserted-by":"publisher","first-page":"15825","DOI":"10.1073\/pnas.0908358106","volume":"106","author":"VT Ho","year":"2009","unstructured":"Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009;106(37):15825\u201330. https:\/\/doi.org\/10.1073\/pnas.0908358106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"662_CR155","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1172\/JCI69098","volume":"123","author":"UE Burkhardt","year":"2013","unstructured":"Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013;123(9):3756\u201365. https:\/\/doi.org\/10.1172\/JCI69098.","journal-title":"J Clin Invest"},{"issue":"10","key":"662_CR156","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1349-7006.1999.tb00686.x","volume":"90","author":"S Fujii","year":"1999","unstructured":"Fujii S, Shimizu K, Fujimoto K, Kiyokawa T, Shimomura T, Kinoshita M, Kawano F. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res. 1999;90(10):1117\u201329. https:\/\/doi.org\/10.1111\/j.1349-7006.1999.tb00686.x.","journal-title":"Jpn J Cancer Res"},{"issue":"7","key":"662_CR157","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.bjc.6601225","volume":"89","author":"A Stam","year":"2003","unstructured":"Stam A, Santegoets S, Westers T, Sombroek C, Janssen J, Tillman B, et al. CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br J Cancer. 2003;89(7):1162\u20135.","journal-title":"Br J Cancer"},{"issue":"7","key":"662_CR158","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00262-004-0631-8","volume":"54","author":"L Li","year":"2005","unstructured":"Li L, Reinhardt P, Schmitt A, Barth TF, Greiner J, Ringhoffer M, et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother. 2005;54(7):685\u201393. https:\/\/doi.org\/10.1007\/s00262-004-0631-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"662_CR159","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.4049\/jimmunol.173.4.2855","volume":"173","author":"A Cignetti","year":"2004","unstructured":"Cignetti A, Vallario A, Roato I, Circosta P, Allione B, Casorzo L, et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J Immunol. 2004;173(4):2855\u201365.","journal-title":"J Immunol"},{"issue":"5","key":"662_CR160","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1537-2995.2007.01616.x","volume":"48","author":"A Schmitt","year":"2008","unstructured":"Schmitt A, Li L, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M, Schmitt M. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion. 2008;48(5):861\u201370. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01616.x.","journal-title":"Transfusion"},{"issue":"1","key":"662_CR161","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2217\/imt.09.85","volume":"2","author":"W van den Ancker","year":"2010","unstructured":"van den Ancker W, van Luijn MM, Westers TM, Bontkes HJ, Ruben JM, de Gruijl TD, et al. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy. 2010;2(1):69\u201383. https:\/\/doi.org\/10.2217\/imt.09.85.","journal-title":"Immunotherapy"},{"issue":"1","key":"662_CR162","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1189\/jlb.0602267","volume":"73","author":"S Fujii","year":"2003","unstructured":"Fujii S, Shimizu K, Koji F, Kawano F. Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential. J Leukoc Biol. 2003;73(1):82\u201390. https:\/\/doi.org\/10.1189\/jlb.0602267.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"662_CR163","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/14653240600735743","volume":"8","author":"MR Litzow","year":"2006","unstructured":"Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, et al. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy. 2006;8(3):290\u20138. https:\/\/doi.org\/10.1080\/14653240600735743.","journal-title":"Cytotherapy"},{"issue":"2","key":"662_CR164","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1365-2141.2006.05997.x","volume":"133","author":"H Roddie","year":"2006","unstructured":"Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, et al. Phase I\/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 2006;133(2):152\u20137. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.05997.x.","journal-title":"Br J Haematol"},{"issue":"10","key":"662_CR165","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/sj.leu.2404348","volume":"20","author":"I Houtenbos","year":"2006","unstructured":"Houtenbos I, Westers TM, Hess CJ, Waisfisz Q, Ossenkoppele GJ, van de Loosdrecht AA. Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells. Leukemia. 2006;20(10):1892\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2404348.","journal-title":"Leukemia"},{"issue":"6","key":"662_CR166","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3109\/14653249.2012.693744","volume":"14","author":"S Anguille","year":"2012","unstructured":"Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy. 2012;14(6):647\u201356.","journal-title":"Cytotherapy"},{"issue":"5","key":"662_CR167","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.molcel.2015.03.027","volume":"58","author":"A Rybak-Wolf","year":"2015","unstructured":"Rybak-Wolf A, Stottmeister C, Glazar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58(5):870\u201385. https:\/\/doi.org\/10.1016\/j.molcel.2015.03.027.","journal-title":"Mol Cell"},{"issue":"2","key":"662_CR168","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105\u201315. https:\/\/doi.org\/10.1111\/imm.12036.","journal-title":"Immunology"},{"issue":"5","key":"662_CR169","doi-asserted-by":"publisher","first-page":"651","DOI":"10.7150\/ijbs.7.651","volume":"7","author":"BF Zamarron","year":"2011","unstructured":"Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651.","journal-title":"Int J Biol Sci"},{"issue":"23","key":"662_CR170","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1182\/blood.V126.23.4218.4218","volume":"126","author":"J Rosenblatt","year":"2015","unstructured":"Rosenblatt J, Avivi I, Binyamini N, Uhl L, Somaiya P, Stroopinsky D, et al. Blockade of PD-1 in combination with dendritic cell\/myeloma fusion cell vaccination following autologous stem cell transplantation is well tolerated, induces anti-tumor immunity and may lead to eradication of measureable disease. Blood. 2015;126(23):4218.","journal-title":"Blood"},{"key":"662_CR171","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00262-009-0756-x","volume":"59","author":"N Hardwick","year":"2010","unstructured":"Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol Immunother. 2010;59:379\u201388.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"662_CR172","first-page":"1736","volume":"114","author":"IM Borrello","year":"2009","unstructured":"Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)\u2013secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood J Am Soc Hematol. 2009;114(9):1736\u201345.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"662_CR173","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/imm.12087","volume":"139","author":"JY Henry","year":"2013","unstructured":"Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C. Enhanced cross-priming of naive CD 8+ T cells by dendritic cells treated by the IM i D s\u00ae immunomodulatory compounds lenalidomide and pomalidomide. Immunology. 2013;139(3):377\u201385.","journal-title":"Immunology"},{"issue":"1","key":"662_CR174","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","volume":"62","author":"K Luptakova","year":"2013","unstructured":"Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013;62(1):39\u201349. https:\/\/doi.org\/10.1007\/s00262-012-1308-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"662_CR175","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","volume":"34","author":"J Rosenblatt","year":"2011","unstructured":"Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine. J Immunother. 2011;34(5):409\u201318. https:\/\/doi.org\/10.1097\/CJI.0b013e31821ca6ce.","journal-title":"J Immunother"},{"issue":"4","key":"662_CR176","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"1","key":"662_CR177","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/srep03571","volume":"4","author":"G Zhang","year":"2014","unstructured":"Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep. 2014;4(1):3571. https:\/\/doi.org\/10.1038\/srep03571.","journal-title":"Sci Rep"},{"issue":"16","key":"662_CR178","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1111\/j.1742-4658.2011.08207.x","volume":"278","author":"A Chailyan","year":"2011","unstructured":"Chailyan A, Marcatili P, Tramontano A. The association of heavy and light chain variable domains in antibodies: implications for antigen specificity. FEBS J. 2011;278(16):2858\u201366. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08207.x.","journal-title":"FEBS J"},{"issue":"2","key":"662_CR179","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125\u201335.","journal-title":"Cancer Immunol Res"},{"key":"662_CR180","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"MC Jensen","year":"2015","unstructured":"Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015;33:9\u201315. https:\/\/doi.org\/10.1016\/j.coi.2015.01.002.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"662_CR181","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494\u2013502. https:\/\/doi.org\/10.1016\/j.it.2015.06.004.","journal-title":"Trends Immunol"},{"issue":"3","key":"662_CR182","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","volume":"28","author":"RD Guest","year":"2005","unstructured":"Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O\u2019Neill A, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203\u201311. https:\/\/doi.org\/10.1097\/01.cji.0000161397.96582.59.","journal-title":"J Immunother"},{"issue":"5","key":"662_CR183","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/gt.2015.4","volume":"22","author":"H Almasbak","year":"2015","unstructured":"Almasbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 2015;22(5):391\u2013403. https:\/\/doi.org\/10.1038\/gt.2015.4.","journal-title":"Gene Ther"},{"issue":"12","key":"662_CR184","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","volume":"184","author":"JS Bridgeman","year":"2010","unstructured":"Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3\u03b6 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex. J Immunol. 2010;184(12):6938\u201349.","journal-title":"J Immunol"},{"issue":"1","key":"662_CR185","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4\u20131BB costimulation. JCI insight. 2018;3(1): e96976.","journal-title":"JCI insight"},{"issue":"1","key":"662_CR186","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107\u201326. https:\/\/doi.org\/10.1111\/imr.12131.","journal-title":"Immunol Rev"},{"issue":"11","key":"662_CR187","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJ, Sievers SA, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452\u201365.","journal-title":"Mol Ther"},{"issue":"3","key":"662_CR188","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"662_CR189","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","volume":"181","author":"T Brocker","year":"1995","unstructured":"Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653\u20139.","journal-title":"J Exp Med"},{"issue":"6","key":"662_CR190","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","volume":"112","author":"BG Till","year":"2008","unstructured":"Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261\u201371. https:\/\/doi.org\/10.1182\/blood-2007-12-128843.","journal-title":"Blood"},{"key":"662_CR191","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","volume":"5","author":"KM Hege","year":"2017","unstructured":"Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5:22. https:\/\/doi.org\/10.1186\/s40425-017-0222-9.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"662_CR192","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat Biotechnol. 2002;20(1):70\u20135. https:\/\/doi.org\/10.1038\/nbt0102-70.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"662_CR193","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, Campana D. Chimeric receptors with 4\u20131BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676\u201384. https:\/\/doi.org\/10.1038\/sj.leu.2403302.","journal-title":"Leukemia"},{"issue":"2","key":"662_CR194","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380\u201390.","journal-title":"Immunity"},{"issue":"7","key":"662_CR195","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ van der Stegen","year":"2015","unstructured":"van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499\u2013509. https:\/\/doi.org\/10.1038\/nrd4597.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"662_CR196","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pul\u00e8","year":"2005","unstructured":"Pul\u00e8 MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12(5):933\u201341.","journal-title":"Mol Ther"},{"issue":"2","key":"662_CR197","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4\u20131BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413\u201320. https:\/\/doi.org\/10.1038\/mt.2009.210.","journal-title":"Mol Ther"},{"issue":"12","key":"662_CR198","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/hum.2013.209","volume":"25","author":"D Abate-Daga","year":"2014","unstructured":"Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 2014;25(12):1003\u201312. https:\/\/doi.org\/10.1089\/hum.2013.209.","journal-title":"Hum Gene Ther"},{"issue":"8","key":"662_CR199","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453\u201364. https:\/\/doi.org\/10.1038\/mt.2009.83.","journal-title":"Mol Ther"},{"issue":"7","key":"662_CR200","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","volume":"124","author":"S Guedan","year":"2014","unstructured":"Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells. Blood. 2014;124(7):1070\u201380. https:\/\/doi.org\/10.1182\/blood-2013-10-535245.","journal-title":"Blood"},{"issue":"4","key":"662_CR201","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4161\/onci.19458","volume":"1","author":"DG Song","year":"2012","unstructured":"Song DG, Powell DJ. Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy. Oncoimmunology. 2012;1(4):547\u20139. https:\/\/doi.org\/10.4161\/onci.19458.","journal-title":"Oncoimmunology"},{"issue":"4","key":"662_CR202","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012;1(4):458\u201366. https:\/\/doi.org\/10.4161\/onci.19855.","journal-title":"Oncoimmunology"},{"issue":"3","key":"662_CR203","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361. https:\/\/doi.org\/10.1038\/s41568-020-00323-z.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"662_CR204","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.4049\/jimmunol.151.11.6577","volume":"151","author":"I Stancovski","year":"1993","unstructured":"Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol. 1993;151(11):6577\u201382.","journal-title":"J Immunol"},{"key":"662_CR205","volume-title":"The T-body approach: potential for cancer immunotherapy. Springer seminars in immunopathology","year":"1996","unstructured":"Eshhar Z, Bach N, Fitzer-Attas CJ, Grosse G, Lustgarten J, Waks T, Schindler DG, editors. The T-body approach: potential for cancer immunotherapy. Springer seminars in immunopathology. Springer; 1996."},{"issue":"1","key":"662_CR206","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1084\/jem.178.1.361","volume":"178","author":"P Hwu","year":"1993","unstructured":"Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 1993;178(1):361\u20136. https:\/\/doi.org\/10.1084\/jem.178.1.361.","journal-title":"J Exp Med"},{"issue":"15","key":"662_CR207","first-page":"3369","volume":"55","author":"P Hwu","year":"1995","unstructured":"Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA. In vivo antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes. Cancer Res. 1995;55(15):3369\u201373.","journal-title":"Cancer Res"},{"issue":"20 Pt 1","key":"662_CR208","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1183.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"662_CR209","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998;188(4):619\u201326. https:\/\/doi.org\/10.1084\/jem.188.4.619.","journal-title":"J Exp Med"},{"issue":"4","key":"662_CR210","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1084\/jem.175.4.951","volume":"175","author":"P Vandenberghe","year":"1992","unstructured":"Vandenberghe P, Freeman GJ, Nadler LM, Fletcher MC, Kamoun M, Turka LA, et al. Antibody and B7\/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J Exp Med. 1992;175(4):951\u201360. https:\/\/doi.org\/10.1084\/jem.175.4.951.","journal-title":"J Exp Med"},{"issue":"8","key":"662_CR211","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1103849.","journal-title":"N Engl J Med"},{"issue":"18","key":"662_CR212","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817\u201328. https:\/\/doi.org\/10.1182\/blood-2011-04-348540.","journal-title":"Blood"},{"issue":"95","key":"662_CR213","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.","journal-title":"Sci Transl Med"},{"issue":"177","key":"662_CR214","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38. https:\/\/doi.org\/10.1126\/scitranslmed.3005930.","journal-title":"Sci Transl Med"},{"issue":"10","key":"662_CR215","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nrd.2017.196","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017;16(10):669. https:\/\/doi.org\/10.1038\/nrd.2017.196.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"662_CR216","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","volume":"159","author":"BL Levine","year":"1997","unstructured":"Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB, June CH. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol. 1997;159(12):5921\u201330.","journal-title":"J Immunol"},{"issue":"2","key":"662_CR217","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt0202-143","volume":"20","author":"MV Maus","year":"2002","unstructured":"Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4\u20131BB. Nat Biotechnol. 2002;20(2):143\u20138. https:\/\/doi.org\/10.1038\/nbt0202-143.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"662_CR218","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1182\/blood-2008-06-160945","volume":"112","author":"MP Rubinstein","year":"2008","unstructured":"Rubinstein MP, Lind NA, Purton JF, Filippou P, Best JA, McGhee PA, et al. IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response. Blood. 2008;112(9):3704\u201312. https:\/\/doi.org\/10.1182\/blood-2008-06-160945.","journal-title":"Blood"},{"issue":"7","key":"662_CR219","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00262-019-02354-4","volume":"68","author":"W Gong","year":"2019","unstructured":"Gong W, Hoffmann JM, Stock S, Wang L, Liu Y, Schubert ML, et al. Comparison of IL-2 vs IL-7\/IL-15 for the generation of NY-ESO-1-specific T cells. Cancer Immunol Immunother. 2019;68(7):1195\u2013209. https:\/\/doi.org\/10.1007\/s00262-019-02354-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"662_CR220","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo C-F, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759\u201372.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"662_CR221","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0020234","volume":"2","author":"RS Mitchell","year":"2004","unstructured":"Mitchell RS, Beitzel BF, Schroder ARW, Shinn P, Chen H, Berry CC, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004;2(8): e234.","journal-title":"PLoS Biol"},{"issue":"4","key":"662_CR222","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/s0092-8674(02)00864-4","volume":"110","author":"AR Schroder","year":"2002","unstructured":"Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521\u20139. https:\/\/doi.org\/10.1016\/s0092-8674(02)00864-4.","journal-title":"Cell"},{"issue":"9","key":"662_CR223","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016;126(9):3363\u201376. https:\/\/doi.org\/10.1172\/JCI86721.","journal-title":"J Clin Invest"},{"key":"662_CR224","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","volume":"132","author":"R Benjamin","year":"2018","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Ciocarlie O, Jain N, et al. Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood. 2018;132:896.","journal-title":"Blood"},{"issue":"6481","key":"662_CR225","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. https:\/\/doi.org\/10.1126\/science.aba7365.","journal-title":"Science"},{"issue":"1","key":"662_CR226","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Richter J, Isenberg D, Roddie C. CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transplant. 2025;60(1):6\u20139. https:\/\/doi.org\/10.1038\/s41409-024-02429-6.","journal-title":"Bone Marrow Transplant"},{"key":"662_CR227","doi-asserted-by":"publisher","first-page":"1432799","DOI":"10.3389\/fimmu.2024.1432799","volume":"15","author":"A Ali","year":"2024","unstructured":"Ali A, DiPersio JF. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. Front Immunol. 2024;15:1432799. https:\/\/doi.org\/10.3389\/fimmu.2024.1432799.","journal-title":"Front Immunol"},{"issue":"3","key":"662_CR228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2024.13171","volume":"29","author":"D Sun","year":"2024","unstructured":"Sun D, Shi X, Li S, Wang X, Yang X, Wan M. CAR-T cell therapy: a breakthrough in traditional cancer treatment strategies (Review). Mol Med Rep. 2024;29(3):1\u20139. https:\/\/doi.org\/10.3892\/mmr.2024.13171.","journal-title":"Mol Med Rep"},{"issue":"22","key":"662_CR229","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood.V128.22.2167.2167","volume":"128","author":"BE Barnett","year":"2016","unstructured":"Barnett BE, Hermanson DL, Smith JB, Wang X, Tan Y, Martin CE, et al. piggyBacTM-produced CAR-T cells exhibit stem-cell memory phenotype. Blood. 2016;128(22):2167.","journal-title":"Blood"},{"issue":"7714","key":"662_CR230","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559(7714):405\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0326-5.","journal-title":"Nature"},{"issue":"12","key":"662_CR231","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","volume":"3","author":"K Schober","year":"2019","unstructured":"Schober K, Muller TR, Gokmen F, Grassmann S, Effenberger M, Poltorak M, et al. Orthotopic replacement of T-cell receptor alpha- and beta-chains with preservation of near-physiological T-cell function. Nat Biomed Eng. 2019;3(12):974\u201384. https:\/\/doi.org\/10.1038\/s41551-019-0409-0.","journal-title":"Nat Biomed Eng"},{"issue":"7738","key":"662_CR232","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","volume":"565","author":"DA Silva","year":"2019","unstructured":"Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labao-Almeida C, et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019;565(7738):186\u201391. https:\/\/doi.org\/10.1038\/s41586-018-0830-7.","journal-title":"Nature"},{"issue":"1","key":"662_CR233","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41467-017-01867-9","volume":"8","author":"SR Bailey","year":"2017","unstructured":"Bailey SR, Nelson MH, Majchrzak K, Bowers JS, Wyatt MM, Smith AS, et al. Human CD26(high) T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nat Commun. 2017;8(1):1961. https:\/\/doi.org\/10.1038\/s41467-017-01867-9.","journal-title":"Nat Commun"},{"issue":"3","key":"662_CR234","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/mt.2012.267","volume":"21","author":"DC Deniger","year":"2013","unstructured":"Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther. 2013;21(3):638\u201347. https:\/\/doi.org\/10.1038\/mt.2012.267.","journal-title":"Mol Ther"},{"issue":"2","key":"662_CR235","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol Ther. 2018;26(2):354\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.001.","journal-title":"Mol Ther"},{"issue":"8","key":"662_CR236","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345. https:\/\/doi.org\/10.1038\/nm.3909.","journal-title":"Nat Med"},{"issue":"6","key":"662_CR237","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173(6):1426\u201338. https:\/\/doi.org\/10.1016\/j.cell.2018.03.038.","journal-title":"Cell"},{"issue":"1","key":"662_CR238","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1368604","volume":"7","author":"JJ Lohmueller","year":"2018","unstructured":"Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2018;7(1): e1368604.","journal-title":"Oncoimmunology"},{"issue":"4","key":"662_CR239","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","volume":"113","author":"JS Ma","year":"2016","unstructured":"Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113(4):E450\u20138. https:\/\/doi.org\/10.1073\/pnas.1524193113.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"662_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.61","volume":"6","author":"M Cartellieri","year":"2016","unstructured":"Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6(8): e458. https:\/\/doi.org\/10.1038\/bcj.2016.61.","journal-title":"Blood Cancer J"},{"issue":"3","key":"662_CR241","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. 'Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"374","key":"662_CR242","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013. https:\/\/doi.org\/10.1126\/scitranslmed.aaj2013.","journal-title":"Sci Transl Med"},{"issue":"9","key":"662_CR243","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23(9):2255\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1300.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"662_CR244","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"6","key":"662_CR245","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1910607.","journal-title":"N Engl J Med"},{"issue":"5","key":"662_CR246","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624\u201336. https:\/\/doi.org\/10.1182\/blood.2020007748.","journal-title":"Blood"},{"issue":"18 Pt 1","key":"662_CR247","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18 Pt 1):5426\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0674.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"662_CR248","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11864-016-0406-4","volume":"17","author":"N Singh","year":"2016","unstructured":"Singh N, Frey NV, Grupp SA, Maude SL. CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr Treat Options Oncol. 2016;17(6):28. https:\/\/doi.org\/10.1007\/s11864-016-0406-4.","journal-title":"Curr Treat Options Oncol"},{"issue":"224","key":"662_CR249","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. https:\/\/doi.org\/10.1126\/scitranslmed.3008226.","journal-title":"Sci Transl Med"},{"issue":"9967","key":"662_CR250","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3.","journal-title":"Lancet"},{"issue":"16","key":"662_CR251","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"issue":"12","key":"662_CR252","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1020.","journal-title":"Cancer Discov"},{"issue":"16","key":"662_CR253","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"21","key":"662_CR254","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood.V124.21.2296.2296","volume":"124","author":"NV Frey","year":"2014","unstructured":"Frey NV, Levine BL, Lacey SF, Grupp SA, Maude SL, Schuster SJ, et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Blood. 2014;124(21):2296.","journal-title":"Blood"},{"issue":"23","key":"662_CR255","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","volume":"126","author":"SA Grupp","year":"2015","unstructured":"Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, et al. Durable remissions in children with relapsed\/refractory all treated with t cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood. 2015;126(23):681.","journal-title":"Blood"},{"issue":"6","key":"662_CR256","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol"},{"issue":"303","key":"662_CR257","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415.","journal-title":"Sci Transl Med"},{"issue":"15","key":"662_CR258","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343\u201354. https:\/\/doi.org\/10.1182\/blood-2013-09-529537.","journal-title":"Blood"},{"issue":"8","key":"662_CR259","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29(8):1637\u201347. https:\/\/doi.org\/10.1038\/leu.2015.52.","journal-title":"Leukemia"},{"issue":"4","key":"662_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.101104","volume":"32","author":"SI Gill","year":"2019","unstructured":"Gill SI. How close are we to CAR T-cell therapy for AML? Best Pract Res Clin Haematol. 2019;32(4): 101104.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"19","key":"662_CR261","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.3390\/cancers13194785","volume":"13","author":"E Kittel-Boselli","year":"2021","unstructured":"Kittel-Boselli E, Soto KEG, Loureiro LR, Hoffmann A, Bergmann R, Arndt C, et al. Targeting acute myeloid leukemia using the RevCAR platform: a programmable, switchable and combinatorial strategy. Cancers (Basel). 2021;13(19):4785. https:\/\/doi.org\/10.3390\/cancers13194785.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"662_CR262","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/cancers13225722","volume":"13","author":"M Fleischmann","year":"2021","unstructured":"Fleischmann M, Schnetzke U, Hochhaus A, Scholl S. Management of acute myeloid leukemia: current treatment options and future perspectives. Cancers (Basel). 2021;13(22):5722. https:\/\/doi.org\/10.3390\/cancers13225722.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"662_CR263","first-page":"2100","volume":"53","author":"J Drach","year":"1993","unstructured":"Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res. 1993;53(9):2100\u20134.","journal-title":"Cancer Res"},{"issue":"1","key":"662_CR264","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.imlet.2011.01.001","volume":"136","author":"HY Cho","year":"2011","unstructured":"Cho HY, Choi EK, Lee SW, Kim KH, Park SJ, Lee CK, Lee SW. All-trans retinoic acid induces TLR-5 expression and cell differentiation and promotes flagellin-mediated cell functions in human THP-1 cells. Immunol Lett. 2011;136(1):97\u2013107. https:\/\/doi.org\/10.1016\/j.imlet.2011.01.001.","journal-title":"Immunol Lett"},{"issue":"11","key":"662_CR265","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1158\/0008-5472.CAN-05-4048","volume":"66","author":"H Qi","year":"2006","unstructured":"Qi H, Ratnam M. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res. 2006;66(11):5875\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4048.","journal-title":"Cancer Res"},{"issue":"13","key":"662_CR266","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","volume":"106","author":"DC Taussig","year":"2005","unstructured":"Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086\u201392. https:\/\/doi.org\/10.1182\/blood-2005-03-1072.","journal-title":"Blood"},{"issue":"6","key":"662_CR267","first-page":"1421","volume":"4","author":"PC Caron","year":"1998","unstructured":"Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res. 1998;4(6):1421\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"662_CR268","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3324\/haematol.2012.066613","volume":"98","author":"MA Sekeres","year":"2013","unstructured":"Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98(1):119\u201328. https:\/\/doi.org\/10.3324\/haematol.2012.066613.","journal-title":"Haematologica"},{"issue":"14","key":"662_CR269","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","volume":"19","author":"A Wiernik","year":"2013","unstructured":"Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013;19(14):3844\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0505.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"662_CR270","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.68","volume":"5","author":"GS Laszlo","year":"2015","unstructured":"Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB. T-cell ligands modulate the cytolytic activity of the CD33\/CD3 BiTE antibody construct, AMG 330. Blood Cancer J. 2015;5(8): e340. https:\/\/doi.org\/10.1038\/bcj.2015.68.","journal-title":"Blood Cancer J"},{"issue":"8","key":"662_CR271","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135945","volume":"10","author":"KH Harrington","year":"2015","unstructured":"Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, et al. The broad anti-AML activity of the CD33\/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk. PLoS ONE. 2015;10(8): e0135945.","journal-title":"PLoS ONE"},{"issue":"32","key":"662_CR272","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26(32):5192\u20137. https:\/\/doi.org\/10.1200\/JCO.2007.15.9764.","journal-title":"J Clin Oncol"},{"issue":"3","key":"662_CR273","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3): e994446. https:\/\/doi.org\/10.4161\/2162402X.2014.994446.","journal-title":"Oncoimmunology"},{"issue":"5","key":"662_CR274","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/cancers14051241","volume":"14","author":"P Vishwasrao","year":"2022","unstructured":"Vishwasrao P, Li G, Boucher JC, Smith DL, Hui SK. Emerging CAR T cell strategies for the treatment of AML. Cancers (Basel). 2022;14(5):1241. https:\/\/doi.org\/10.3390\/cancers14051241.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"662_CR275","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138\u201348. https:\/\/doi.org\/10.1182\/blood-2012-12-474056.","journal-title":"Blood"},{"issue":"7","key":"662_CR276","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3324\/haematol.2014.113092","volume":"100","author":"EM Lee","year":"2015","unstructured":"Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015;100(7):914\u201326. https:\/\/doi.org\/10.3324\/haematol.2014.113092.","journal-title":"Haematologica"},{"issue":"4","key":"662_CR277","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","volume":"67","author":"PA Dinndorf","year":"1986","unstructured":"Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67(4):1048\u201353.","journal-title":"Blood"},{"key":"662_CR278","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007811","volume-title":"C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. MAbs","author":"VR Wiersma","year":"2015","unstructured":"Wiersma VR, de Bruyn M, Shi C, Gooden MJ, Wouters MC, Samplonius DF, et al. C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. MAbs. Taylor & Francis; 2015."},{"issue":"9","key":"662_CR279","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","volume":"25","author":"H Tashiro","year":"2017","unstructured":"Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther. 2017;25(9):2202\u201313. https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.024.","journal-title":"Mol Ther"},{"issue":"22","key":"662_CR280","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443\u201350. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1659.","journal-title":"Cancer Res"},{"issue":"8","key":"662_CR281","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","volume":"21","author":"A Van Rhenen","year":"2007","unstructured":"Van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint A, Zweegman S, et al. Aberrant marker expression patterns on the CD34+ CD38\u2212 stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21(8):1700\u20137.","journal-title":"Leukemia"},{"key":"662_CR282","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11:1\u201313.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"662_CR283","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6(9):1018\u201323.","journal-title":"Nat Med"},{"issue":"7290","key":"662_CR284","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature08851","volume":"464","author":"MH Raaijmakers","year":"2010","unstructured":"Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852\u20137. https:\/\/doi.org\/10.1038\/nature08851.","journal-title":"Nature"},{"issue":"3","key":"662_CR285","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3324\/haematol.2010.031674","volume":"96","author":"K Rezvani","year":"2011","unstructured":"Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica. 2011;96(3):432\u201340. https:\/\/doi.org\/10.3324\/haematol.2010.031674.","journal-title":"Haematologica"},{"issue":"16","key":"662_CR286","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1182\/blood-2010-07-299248","volume":"117","author":"A Sergeeva","year":"2011","unstructured":"Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, et al. An anti-PR1\/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011;117(16):4262\u201372. https:\/\/doi.org\/10.1182\/blood-2010-07-299248.","journal-title":"Blood"},{"issue":"24","key":"662_CR287","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1056\/NEJM200106143442402","volume":"344","author":"MJ Laughlin","year":"2001","unstructured":"Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344(24):1815\u201322. https:\/\/doi.org\/10.1056\/NEJM200106143442402.","journal-title":"N Engl J Med"},{"issue":"22","key":"662_CR288","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMoa041276","volume":"351","author":"MJ Laughlin","year":"2004","unstructured":"Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351(22):2265\u201375. https:\/\/doi.org\/10.1056\/NEJMoa041276.","journal-title":"N Engl J Med"},{"issue":"8969","key":"662_CR289","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/s0140-6736(95)91268-1","volume":"346","author":"JE Wagner","year":"1995","unstructured":"Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 1995;346(8969):214\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(95)91268-1.","journal-title":"Lancet"},{"issue":"3","key":"662_CR290","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJM199607183350303","volume":"335","author":"J Kurtzberg","year":"1996","unstructured":"Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335(3):157\u201366.","journal-title":"N Engl J Med"},{"issue":"4","key":"662_CR291","first-page":"318","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood J Am Soc Hematol. 2021;138(4):318\u201330.","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"662_CR292","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, Hopner S, Bacher U, Hinterbrandner M, Banz Y, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26(9):1459\u201367. https:\/\/doi.org\/10.1038\/s41591-020-0910-8.","journal-title":"Nat Med"},{"issue":"6","key":"662_CR293","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, Shima T, Takayanagi SI, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708\u201317.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"662_CR294","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1158\/1078-0432.CCR-16-1421","volume":"23","author":"QJ Wang","year":"2017","unstructured":"Wang QJ, Yu Z, Hanada KI, Patel K, Kleiner D, Restifo NP, Yang JC. Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers. Clin Cancer Res. 2017;23(9):2267\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1421.","journal-title":"Clin Cancer Res"},{"key":"662_CR295","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2021-150596","volume":"138","author":"MB Leick","year":"2021","unstructured":"Leick MB, Silva H, Scarf\u00f2 I, Larson R, Choi BD, Bouffard AA, et al. Rational chemical and genetic modifications enhance avidity and function of CD70-directed CAR-T-cells for myeloid leukemia. Blood. 2021;138:405.","journal-title":"Blood"},{"issue":"4","key":"662_CR296","first-page":"2665","volume":"20","author":"B Bodey","year":"2000","unstructured":"Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 2000;20(4):2665\u201376.","journal-title":"Anticancer Res"},{"issue":"1","key":"662_CR297","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s13287-019-1455-y","volume":"10","author":"S Moradi","year":"2019","unstructured":"Moradi S, Mahdizadeh H, Saric T, Kim J, Harati J, Shahsavarani H, et al. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res Ther. 2019;10(1):341. https:\/\/doi.org\/10.1186\/s13287-019-1455-y.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"662_CR298","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/vaccines8040615","volume":"8","author":"L Buonaguro","year":"2020","unstructured":"Buonaguro L, Tagliamonte M. Selecting target antigens for cancer vaccine development. Vaccines (Basel). 2020;8(4):615. https:\/\/doi.org\/10.3390\/vaccines8040615.","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"662_CR299","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","volume":"9","author":"L Hammerich","year":"2015","unstructured":"Hammerich L, Binder A, Brody JD. In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol. 2015;9(10):1966\u201381.","journal-title":"Mol Oncol"},{"issue":"Pt 1","key":"662_CR300","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/mic.0.049601-0","volume":"159","author":"M Saxena","year":"2013","unstructured":"Saxena M, Van TTH, Baird FJ, Coloe PJ, Smooker PM. Pre-existing immunity against vaccine vectors\u2013friend or foe? Microbiology (Reading). 2013;159(Pt 1):1\u201311. https:\/\/doi.org\/10.1099\/mic.0.049601-0.","journal-title":"Microbiology (Reading)"},{"issue":"3","key":"662_CR301","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/pharmaceutics13030428","volume":"13","author":"JD Torres-Vanegas","year":"2021","unstructured":"Torres-Vanegas JD, Cruz JC, Reyes LH. Delivery systems for nucleic acids and proteins: barriers, cell capture pathways and nanocarriers. Pharmaceutics. 2021;13(3):428. https:\/\/doi.org\/10.3390\/pharmaceutics13030428.","journal-title":"Pharmaceutics"},{"key":"662_CR302","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696791","volume":"12","author":"AJ Stephens","year":"2021","unstructured":"Stephens AJ, Burgess-Brown NA, Jiang S. Beyond just peptide antigens: the complex world of peptide-based cancer vaccines. Front Immunol. 2021;12: 696791.","journal-title":"Front Immunol"},{"issue":"26","key":"662_CR303","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1610497.","journal-title":"N Engl J Med"},{"key":"662_CR304","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2019-131056","volume":"134","author":"H Zhang","year":"2019","unstructured":"Zhang H, Gao L, Liu L, Wang J, Wang S, Gao L, et al. A Bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma. Blood. 2019;134:3147.","journal-title":"Blood"},{"issue":"1","key":"662_CR305","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","volume":"18","author":"Q Lin","year":"2019","unstructured":"Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer. 2019;18(1):154. https:\/\/doi.org\/10.1186\/s12943-019-1092-1.","journal-title":"Mol Cancer"},{"key":"662_CR306","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13:1\u201310.","journal-title":"J Hematol Oncol"},{"key":"662_CR307","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","volume":"132","author":"N Hossain","year":"2018","unstructured":"Hossain N, Sahaf B, Abramian M, Spiegel JY, Kong K, Kim S, et al. Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies. Blood. 2018;132:490.","journal-title":"Blood"},{"issue":"5","key":"662_CR308","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","volume":"32","author":"S Wilkie","year":"2012","unstructured":"Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059\u201370. https:\/\/doi.org\/10.1007\/s10875-012-9689-9.","journal-title":"J Clin Immunol"},{"issue":"8","key":"662_CR309","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036\u201352. https:\/\/doi.org\/10.1172\/JCI83416.","journal-title":"J Clin Invest"},{"issue":"9","key":"662_CR310","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/glycob\/cwy008","volume":"28","author":"C Steentoft","year":"2018","unstructured":"Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD Jr. Glycan-directed CAR-T cells. Glycobiology. 2018;28(9):656\u201369. https:\/\/doi.org\/10.1093\/glycob\/cwy008.","journal-title":"Glycobiology"},{"issue":"2","key":"662_CR311","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"H Du","year":"2019","unstructured":"Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7\u2013H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35(2):221-37 e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.002.","journal-title":"Cancer Cell"},{"issue":"8","key":"662_CR312","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7\u2013H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"662_CR313","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180(7):4901\u20139. https:\/\/doi.org\/10.4049\/jimmunol.180.7.4901.","journal-title":"J Immunol"},{"key":"662_CR314","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru M, O\u2019Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015;13:102. https:\/\/doi.org\/10.1186\/s12967-015-0460-x.","journal-title":"J Transl Med"},{"issue":"14","key":"662_CR315","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1158\/1078-0432.CCR-10-0192","volume":"16","author":"AA Chekmasova","year":"2010","unstructured":"Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, Brentjens RJ. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 2010;16(14):3594\u2013606. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0192.","journal-title":"Clin Cancer Res"},{"key":"662_CR316","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","volume":"9","author":"JP Murad","year":"2018","unstructured":"Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, et al. Effective targeting of TAG72(+) peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front Immunol. 2018;9:2268. https:\/\/doi.org\/10.3389\/fimmu.2018.02268.","journal-title":"Front Immunol"},{"issue":"1","key":"662_CR317","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","volume":"24","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain. Clin Cancer Res. 2018;24(1):95\u2013105. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2041.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"662_CR318","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, et al. Optimization of IL13Ralpha2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018;26(1):31\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.002.","journal-title":"Mol Ther"},{"issue":"261","key":"662_CR319","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261): 261ra151. https:\/\/doi.org\/10.1126\/scitranslmed.3010162.","journal-title":"Sci Transl Med"},{"issue":"5","key":"662_CR320","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cancers11050674","volume":"11","author":"LM Whilding","year":"2019","unstructured":"Whilding LM, Halim L, Draper B, Parente-Pereira AC, Zabinski T, Davies DM, Maher J. CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers. 2019;11(5):674.","journal-title":"Cancers"},{"issue":"5","key":"662_CR321","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50(5):712\u201324.","journal-title":"Eur J Immunol"},{"issue":"1","key":"662_CR322","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, et al. CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10(1):4016.","journal-title":"Nat Commun"},{"issue":"5","key":"662_CR323","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524\u20139. https:\/\/doi.org\/10.1038\/nm.3833.","journal-title":"Nat Med"},{"issue":"2","key":"662_CR324","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LCS Wang","year":"2014","unstructured":"Wang LCS, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2(2):154\u201366.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"662_CR325","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337. https:\/\/doi.org\/10.1038\/nm.3394.","journal-title":"Nat Med"},{"key":"662_CR326","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","volume":"11","author":"Y Yin","year":"2018","unstructured":"Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, et al. Checkpoint blockade reverses anergy in IL-13Ralpha2 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics. 2018;11:20\u201338. https:\/\/doi.org\/10.1016\/j.omto.2018.08.002.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"662_CR327","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471\u201382. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.006.","journal-title":"Cancer Cell"},{"issue":"8","key":"662_CR328","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341. https:\/\/doi.org\/10.1182\/blood-2016-09-738245.","journal-title":"Blood"},{"issue":"7","key":"662_CR329","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855\u201366. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.003.","journal-title":"Mol Ther"},{"issue":"1","key":"662_CR330","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CAR s and TRUCK s: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257(1):83\u201390.","journal-title":"Immunol Rev"},{"issue":"7","key":"662_CR331","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, et al. Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5(7):571\u201381. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0376.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"662_CR332","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25(1):249\u201358. https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.016.","journal-title":"Mol Ther"},{"issue":"1","key":"662_CR333","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):164. https:\/\/doi.org\/10.1186\/s13045-020-01001-1.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"662_CR334","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1709919.","journal-title":"N Engl J Med"},{"issue":"1","key":"662_CR335","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","volume":"2016","author":"NV Frey","year":"2016","unstructured":"Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016(1):567\u201372. https:\/\/doi.org\/10.1182\/asheducation-2016.1.567.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"662_CR336","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319.","journal-title":"Cancer Discov"},{"issue":"1","key":"662_CR337","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/MOH.0000000000000559","volume":"27","author":"RM Sterner","year":"2020","unstructured":"Sterner RM, Kenderian SS. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Curr Opin Hematol. 2020;27(1):41\u20138. https:\/\/doi.org\/10.1097\/MOH.0000000000000559.","journal-title":"Curr Opin Hematol"},{"issue":"26","key":"662_CR338","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"5","key":"662_CR339","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"1","key":"662_CR340","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"662_CR341","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"662_CR342","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"issue":"10","key":"662_CR343","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442.","journal-title":"Cancer Discov"},{"issue":"26","key":"662_CR344","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323. https:\/\/doi.org\/10.1182\/blood-2014-12-580068.","journal-title":"Blood"},{"issue":"Supplement 1","key":"662_CR345","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","volume":"132","author":"DJ Green","year":"2018","unstructured":"Green DJ, Pont M, Sather BD, Cowan AJ, Turtle CJ, Till BG, et al. Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood. 2018;132(Supplement 1):1011.","journal-title":"Blood"},{"issue":"22","key":"662_CR346","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267\u201380. https:\/\/doi.org\/10.1200\/JCO.2018.77.8084.","journal-title":"J Clin Oncol"},{"issue":"6","key":"662_CR347","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210\u201321. https:\/\/doi.org\/10.1172\/JCI126397.","journal-title":"J Clin Invest"},{"issue":"4","key":"662_CR348","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","volume":"59","author":"BL Zhang","year":"2016","unstructured":"Zhang BL, Qin DY, Mo ZM, Li Y, Wei W, Wang YS, et al. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci China Life Sci. 2016;59(4):340\u20138. https:\/\/doi.org\/10.1007\/s11427-016-5027-4.","journal-title":"Sci China Life Sci"},{"key":"662_CR349","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","volume":"132","author":"AM Li","year":"2018","unstructured":"Li AM, Hucks GE, Dinofia AM, Seif AE, Teachey DT, Baniewicz D, et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. Blood. 2018;132:556.","journal-title":"Blood"},{"issue":"7","key":"662_CR350","first-page":"1979","volume":"10","author":"M Huang","year":"2020","unstructured":"Huang M, Deng J, Gao L, Zhou J. Innovative strategies to advance CAR T cell therapy for solid tumors. Am J Cancer Res. 2020;10(7):1979\u201392.","journal-title":"Am J Cancer Res"},{"key":"662_CR351","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.phrs.2017.11.035","volume":"129","author":"MC Ramello","year":"2018","unstructured":"Ramello MC, Haura EB, Abate-Daga D. CAR-T cells and combination therapies: What\u2019s next in the immunotherapy revolution? Pharmacol Res. 2018;129:194\u2013203. https:\/\/doi.org\/10.1016\/j.phrs.2017.11.035.","journal-title":"Pharmacol Res"},{"issue":"1","key":"662_CR352","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22(1):365. https:\/\/doi.org\/10.1186\/s12935-022-02778-6.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"662_CR353","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844\u201353. https:\/\/doi.org\/10.1038\/s41591-023-02612-0.","journal-title":"Nat Med"},{"issue":"1","key":"662_CR354","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/0115748871260733231031081921","volume":"19","author":"C Chandarana","year":"2024","unstructured":"Chandarana C, Tiwari A. A review of clinical trials of cancer and its treatment as a vaccine. Rev Recent Clin Trials. 2024;19(1):7\u201333.","journal-title":"Rev Recent Clin Trials"},{"issue":"4","key":"662_CR355","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","volume":"16","author":"DT Le","year":"2010","unstructured":"Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. 2010;16(4):304\u201310. https:\/\/doi.org\/10.1097\/PPO.0b013e3181eb33d7.","journal-title":"Cancer J"},{"issue":"13","key":"662_CR356","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1158\/1078-0432.CCR-14-2998","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Weber G, Ballard BC, Wood MS, Savoldo B, Dotti G. K562-derived whole-cell vaccine enhances antitumor responses of CAR-redirected virus-specific cytotoxic T lymphocytes in vivo. Clin Cancer Res. 2015;21(13):2952\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2998.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"662_CR357","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/leu.2017.39","volume":"31","author":"C Rossig","year":"2017","unstructured":"Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2017;31(5):1087\u201395. https:\/\/doi.org\/10.1038\/leu.2017.39.","journal-title":"Leukemia"},{"key":"662_CR358","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.omtm.2017.03.004","volume":"5","author":"M Weinstock","year":"2017","unstructured":"Weinstock M, Rosenblatt J, Avigan D. Dendritic cell therapies for hematologic malignancies. Mol Ther Methods Clin Dev. 2017;5:66\u201375. https:\/\/doi.org\/10.1016\/j.omtm.2017.03.004.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"662_CR359","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jcyt.2019.03.313","volume":"21","author":"M Wu","year":"2019","unstructured":"Wu M, Zhang L, Zhang H, Ning J, Tu S, He Y, Li Y. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia. Cytotherapy. 2019;21(6):659\u201370. https:\/\/doi.org\/10.1016\/j.jcyt.2019.03.313.","journal-title":"Cytotherapy"},{"issue":"7","key":"662_CR360","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1157","volume":"9","author":"JD Chan","year":"2020","unstructured":"Chan JD, von Scheidt B, Zeng B, Oliver AJ, Davey AS, Ali AI, et al. Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells. Clin Transl Immunol. 2020;9(7): e1157. https:\/\/doi.org\/10.1002\/cti2.1157.","journal-title":"Clin Transl Immunol"},{"issue":"6476","key":"662_CR361","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446\u201353. https:\/\/doi.org\/10.1126\/science.aay5967.","journal-title":"Science"},{"issue":"1","key":"662_CR362","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","volume":"20","author":"JD Beck","year":"2021","unstructured":"Beck JD, Reidenbach D, Salomon N, Sahin U, Tureci O, Vormehr M, Kranz LM. mRNA therapeutics in cancer immunotherapy. Mol Cancer. 2021;20(1):69. https:\/\/doi.org\/10.1186\/s12943-021-01348-0.","journal-title":"Mol Cancer"},{"issue":"4","key":"662_CR363","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2004-03-1208","volume":"105","author":"LJ Cooper","year":"2005","unstructured":"Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105(4):1622\u201331. https:\/\/doi.org\/10.1182\/blood-2004-03-1208.","journal-title":"Blood"},{"issue":"17","key":"662_CR364","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965\u201373. https:\/\/doi.org\/10.1182\/blood-2013-06-506741.","journal-title":"Blood"},{"issue":"14","key":"662_CR365","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-16-2138","volume":"23","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, et al. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells. Clin Cancer Res. 2017;23(14):3499\u2013509. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2138.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"662_CR366","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1158\/1078-0432.CCR-14-2920","volume":"21","author":"X Wang","year":"2015","unstructured":"Wang X, Wong CW, Urak R, Mardiros A, Budde LE, Chang WC, et al. CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells. Clin Cancer Res. 2015;21(13):2993\u20133002. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2920.","journal-title":"Clin Cancer Res"},{"key":"662_CR367","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100695","volume":"45","author":"R Bansal","year":"2021","unstructured":"Bansal R, Reshef R. Revving the CAR\u2013Combination strategies to enhance CAR T cell effectiveness. Blood Rev. 2021;45: 100695.","journal-title":"Blood Rev"},{"issue":"4","key":"662_CR368","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"662_CR369","doi-asserted-by":"publisher","first-page":"17","DOI":"10.6004\/jadpro.2021.12.1.1","volume":"12","author":"B Faiman","year":"2021","unstructured":"Faiman B. Approved mRNA vaccines for SARS-CoV-2. J Adv Pract Oncol. 2021;12(1):17\u20138. https:\/\/doi.org\/10.6004\/jadpro.2021.12.1.1.","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"662_CR370","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1083\/jcb.103.1.23","volume":"103","author":"EJ Aamodt","year":"1986","unstructured":"Aamodt EJ, Culotti JG. Microtubules and microtubule-associated proteins from the nematode Caenorhabditis elegans: periodic cross-links connect microtubules in vitro. J Cell Biol. 1986;103(1):23\u201331. https:\/\/doi.org\/10.1083\/jcb.103.1.23.","journal-title":"J Cell Biol"},{"issue":"12","key":"662_CR371","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","volume":"25","author":"F Liang","year":"2017","unstructured":"Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Rohss J, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther. 2017;25(12):2635\u201347. https:\/\/doi.org\/10.1016\/j.ymthe.2017.08.006.","journal-title":"Mol Ther"},{"issue":"7607","key":"662_CR372","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396\u2013401. https:\/\/doi.org\/10.1038\/nature18300.","journal-title":"Nature"},{"issue":"6","key":"662_CR373","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s00262-005-0064-z","volume":"55","author":"PR Hess","year":"2006","unstructured":"Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor\/self antigen. Cancer Immunol Immunother. 2006;55(6):672\u201383.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"662_CR374","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ijc.28857","volume":"135","author":"P Micke","year":"2014","unstructured":"Micke P, Mattsson JSM, Edlund K, Lohr M, Jirstr\u00f6m K, Berglund A, et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer. 2014;135(9):2206\u201314.","journal-title":"Int J Cancer"},{"issue":"3","key":"662_CR375","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2021.12316","volume":"24","author":"H Du","year":"2021","unstructured":"Du H, Yang X, Fan J, Du X. Claudin 6: therapeutic prospects for tumours, and mechanisms of expression and regulation (Review). Mol Med Rep. 2021;24(3):1\u20139. https:\/\/doi.org\/10.3892\/mmr.2021.12316.","journal-title":"Mol Med Rep"},{"key":"662_CR376","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1471-2407-6-186","volume":"6","author":"KJ Hewitt","year":"2006","unstructured":"Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186. https:\/\/doi.org\/10.1186\/1471-2407-6-186.","journal-title":"BMC Cancer"},{"key":"662_CR377","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.726656","volume":"9","author":"C Zhang","year":"2021","unstructured":"Zhang C, Guo C, Li Y, Liu K, Zhao Q, Ouyang L. Identification of claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis. Front Cell Dev Biol. 2021;9: 726656.","journal-title":"Front Cell Dev Biol"},{"issue":"12_Supplement","key":"662_CR378","doi-asserted-by":"publisher","first-page":"CT002-CT","DOI":"10.1158\/1538-7445.AM2022-CT002","volume":"82","author":"JB Haanen","year":"2022","unstructured":"Haanen JB, Mackensen A, Koenecke C, Alsdorf W, Wagner-Drouet E, Heudobler D, et al. Abstract CT002: BNT211: a phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. Cancer Res. 2022;82(12_Supplement):CT002-CT.","journal-title":"Cancer Res"},{"issue":"1","key":"662_CR379","first-page":"8030440","volume":"2023","author":"EO Ansah","year":"2023","unstructured":"Ansah EO, Baah A, Agyenim EB. Vaccine boosting CAR-T cell therapy: current and future strategies. Adv Cell Gene Ther. 2023;2023(1):8030440.","journal-title":"Adv Cell Gene Ther"},{"issue":"7","key":"662_CR380","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2021013896","volume":"139","author":"JY Spiegel","year":"2022","unstructured":"Spiegel JY, Komanduri KV. Treating CAR-T relapses: check not checkmate. Blood. 2022;139(7):955\u20137. https:\/\/doi.org\/10.1182\/blood.2021013896.","journal-title":"Blood"},{"issue":"1","key":"662_CR381","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2021.103320","volume":"70","author":"L Wang","year":"2022","unstructured":"Wang L. Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Curr Res Transl Med. 2022;70(1): 103320. https:\/\/doi.org\/10.1016\/j.retram.2021.103320.","journal-title":"Curr Res Transl Med"},{"issue":"22","key":"662_CR382","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607\u201315. https:\/\/doi.org\/10.1182\/bloodadvances.2020003001.","journal-title":"Blood Adv"},{"key":"662_CR383","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H. The EBMT\/EHA CAR-T cell handbook; 2022.","DOI":"10.1007\/978-3-030-94353-0"},{"key":"662_CR384","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664. https:\/\/doi.org\/10.3389\/fimmu.2019.02664.","journal-title":"Front Immunol"},{"issue":"11","key":"662_CR385","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HT Khong","year":"2002","unstructured":"Khong HT, Restifo NP. Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes. Nat Immunol. 2002;3(11):999\u20131005.","journal-title":"Nat Immunol"},{"issue":"10","key":"662_CR386","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00262-006-0164-4","volume":"55","author":"TB Tomasi","year":"2006","unstructured":"Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother. 2006;55(10):1159\u201384. https:\/\/doi.org\/10.1007\/s00262-006-0164-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"662_CR387","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00262-003-0485-5","volume":"53","author":"S Satthaporn","year":"2004","unstructured":"Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother. 2004;53(6):510\u20138. https:\/\/doi.org\/10.1007\/s00262-003-0485-5.","journal-title":"Cancer Immunol Immunother"},{"key":"662_CR388","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2018.03.025","volume":"113","author":"J Bandola-Simon","year":"2019","unstructured":"Bandola-Simon J, Roche PA. Dysfunction of antigen processing and presentation by dendritic cells in cancer. Mol Immunol. 2019;113:31\u20137. https:\/\/doi.org\/10.1016\/j.molimm.2018.03.025.","journal-title":"Mol Immunol"},{"issue":"677","key":"662_CR389","doi-asserted-by":"publisher","first-page":"eabo4778","DOI":"10.1126\/scitranslmed.abo4778","volume":"15","author":"KS Chen","year":"2023","unstructured":"Chen KS, Reinshagen C, Van Schaik TA, Rossignoli F, Borges P, Mendonca NC, et al. Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity. Sci Transl Med. 2023;15(677):eabo4778. https:\/\/doi.org\/10.1126\/scitranslmed.abo4778.","journal-title":"Sci Transl Med"},{"key":"662_CR390","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fimmu.2018.00350","volume":"9","author":"H Hasegawa","year":"2018","unstructured":"Hasegawa H, Matsumoto T. Mechanisms of tolerance induction by dendritic cells in vivo. Front Immunol. 2018;9:350. https:\/\/doi.org\/10.3389\/fimmu.2018.00350.","journal-title":"Front Immunol"},{"issue":"1","key":"662_CR391","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12967-016-0916-7","volume":"14","author":"G Stallone","year":"2016","unstructured":"Stallone G, Infante B, Di Lorenzo A, Rascio F, Zaza G, Grandaliano G. mTOR inhibitors effects on regulatory T cells and on dendritic cells. J Transl Med. 2016;14(1):152. https:\/\/doi.org\/10.1186\/s12967-016-0916-7.","journal-title":"J Transl Med"},{"issue":"2","key":"662_CR392","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.193.2.233","volume":"193","author":"MV Dhodapkar","year":"2001","unstructured":"Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193(2):233\u20138. https:\/\/doi.org\/10.1084\/jem.193.2.233.","journal-title":"J Exp Med"},{"issue":"3","key":"662_CR393","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136. https:\/\/doi.org\/10.1038\/icb.2014.93.","journal-title":"Immunol Cell Biol"},{"issue":"22","key":"662_CR394","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-21-1141","volume":"27","author":"AI Ali","year":"2021","unstructured":"Ali AI, Wang M, von Scheidt B, Dominguez PM, Harrison AJ, Tantalo DGM, et al. A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer. Clin Cancer Res. 2021;27(22):6222\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1141.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"662_CR395","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24(6):399\u2013416. https:\/\/doi.org\/10.1038\/s41577-023-00973-8.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"662_CR396","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/cancers16040754","volume":"16","author":"I Elmakaty","year":"2024","unstructured":"Elmakaty I, Saglio G, Al-Khabori M, Elsayed A, Elsayed B, Elmarasi M, et al. The contemporary role of hematopoietic stem cell transplantation in the management of chronic myeloid leukemia: is it the same in all settings? Cancers. 2024;16(4):754.","journal-title":"Cancers"},{"issue":"1","key":"662_CR397","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41408-024-01122-7","volume":"14","author":"ASR Westerveld","year":"2024","unstructured":"Westerveld ASR, Roesthuis P, van der Pal HJH, Bresters D, Bierings M, Loonen J, et al. Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia. Blood Cancer J. 2024;14(1):150. https:\/\/doi.org\/10.1038\/s41408-024-01122-7.","journal-title":"Blood Cancer J"},{"issue":"18","key":"662_CR398","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/bloodadvances.2021004453C","volume":"5","author":"S Lesch","year":"2021","unstructured":"Lesch S, Gill S. The promise and perils of immunotherapy. Blood Adv. 2021;5(18):3709\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2021004453C.","journal-title":"Blood Adv"},{"key":"662_CR399","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165673","author":"X Li","year":"2023","unstructured":"Li X, Li Y, Dong L, Chang Y, Zhang X, Wang C, et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI165673.","journal-title":"J Clin Invest"},{"issue":"1","key":"662_CR400","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12(1):409. https:\/\/doi.org\/10.1038\/s41467-020-20696-x.","journal-title":"Nat Commun"},{"issue":"6","key":"662_CR401","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cac2.12313","volume":"42","author":"Y Xu","year":"2022","unstructured":"Xu Y, Li P, Liu Y, Xin D, Lei W, Liang A, et al. Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials. Cancer Commun (Lond). 2022;42(6):493\u2013516. https:\/\/doi.org\/10.1002\/cac2.12313.","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"662_CR402","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2352-3026(23)00064-9","volume":"10","author":"NJ Short","year":"2023","unstructured":"Short NJ, Kantarjian H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematol. 2023;10(5):e382\u20138. https:\/\/doi.org\/10.1016\/S2352-3026(23)00064-9.","journal-title":"Lancet Haematol"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00662-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00662-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00662-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T06:03:21Z","timestamp":1747461801000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00662-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":402,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00662-3","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve any animal or human experimental models. Hence, ethical approval is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read the final version of the manuscript and declared their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}